We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment Program for Anemia in AIDS Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00002022
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
NIH AIDS Clinical Trials Information Service
  Purpose
The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Condition Intervention
HIV Infections Cytopenias Drug: Epoetin alfa

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Program for Anemia in AIDS Patients

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

  • A clinical diagnosis of AIDS.
  • Hematocrit < 30 percent.
  • Endogenous serum erythropoietin level = or < 500 U/ml.
  • A life expectancy = or > 3 months.
  • > Grade 4 performance score.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002022


Locations
United States, New Jersey
R W Johnson Pharmaceutical Research Institute
Raritan, New Jersey, United States, 088690602
Sponsors and Collaborators
R W Johnson Pharmaceutical Research Institute
  More Information

ClinicalTrials.gov Identifier: NCT00002022     History of Changes
Other Study ID Numbers: 004G
I88-083
First Submitted: November 2, 1999
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Last Verified: February 1991

Keywords provided by NIH AIDS Clinical Trials Information Service:
Recombinant Proteins
Drugs, Investigational
Erythropoietin
Acquired Immunodeficiency Syndrome
Anemia
Zidovudine

Additional relevant MeSH terms:
Anemia
HIV Infections
Hematologic Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Epoetin Alfa
Hematinics